Evidence map›Paper›PMID 36128684›Full record

Trial reportThe American journal of psychiatry2022

A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial.

Rebecca B Price, Crystal Spotts, Benjamin Panny, Angela Griffo, Michelle Degutis, Nicolas Cruz, Elizabeth Bell, Kevin Do-Nguyen, Meredith L Wallace, Sanjay J Mathew and 1 more

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The American journal of psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
11.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 70 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Psilocybin: From Psychiatric Pariah to Perceived Panacea.The American journal of psychiatry · 2025
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Rebecca B PriceUniversity of Pittsburgh School of Medicine, Pittsburgh (Price, Spotts, Panny, Griffo, Degutis, Cruz, Bell, Do-Nguyen, Wallace, Howland); Baylor College School of Medicine and Michael E. DeBakey VA Medical Center, Houston (Mathew).
Crystal SpottsUniversity of Pittsburgh School of Medicine, Pittsburgh (Price, Spotts, Panny, Griffo, Degutis, Cruz, Bell, Do-Nguyen, Wallace, Howland); Baylor College School of Medicine and Michael E. DeBakey VA Medical Center, Houston (Mathew).
Benjamin PannyUniversity of Pittsburgh School of Medicine, Pittsburgh (Price, Spotts, Panny, Griffo, Degutis, Cruz, Bell, Do-Nguyen, Wallace, Howland); Baylor College School of Medicine and Michael E. DeBakey VA Medical Center, Houston (Mathew).
Angela GriffoUniversity of Pittsburgh School of Medicine, Pittsburgh (Price, Spotts, Panny, Griffo, Degutis, Cruz, Bell, Do-Nguyen, Wallace, Howland); Baylor College School of Medicine and Michael E. DeBakey VA Medical Center, Houston (Mathew).
Michelle DegutisUniversity of Pittsburgh School of Medicine, Pittsburgh (Price, Spotts, Panny, Griffo, Degutis, Cruz, Bell, Do-Nguyen, Wallace, Howland); Baylor College School of Medicine and Michael E. DeBakey VA Medical Center, Houston (Mathew).
Nicolas CruzUniversity of Pittsburgh School of Medicine, Pittsburgh (Price, Spotts, Panny, Griffo, Degutis, Cruz, Bell, Do-Nguyen, Wallace, Howland); Baylor College School of Medicine and Michael E. DeBakey VA Medical Center, Houston (Mathew).
Elizabeth BellUniversity of Pittsburgh School of Medicine, Pittsburgh (Price, Spotts, Panny, Griffo, Degutis, Cruz, Bell, Do-Nguyen, Wallace, Howland); Baylor College School of Medicine and Michael E. DeBakey VA Medical Center, Houston (Mathew).
Kevin Do-NguyenUniversity of Pittsburgh School of Medicine, Pittsburgh (Price, Spotts, Panny, Griffo, Degutis, Cruz, Bell, Do-Nguyen, Wallace, Howland); Baylor College School of Medicine and Michael E. DeBakey VA Medical Center, Houston (Mathew).
Meredith L WallaceUniversity of Pittsburgh School of Medicine, Pittsburgh (Price, Spotts, Panny, Griffo, Degutis, Cruz, Bell, Do-Nguyen, Wallace, Howland); Baylor College School of Medicine and Michael E. DeBakey VA Medical Center, Houston (Mathew).
Sanjay J MathewUniversity of Pittsburgh School of Medicine, Pittsburgh (Price, Spotts, Panny, Griffo, Degutis, Cruz, Bell, Do-Nguyen, Wallace, Howland); Baylor College School of Medicine and Michael E. DeBakey VA Medical Center, Houston (Mathew).
Robert H HowlandUniversity of Pittsburgh School of Medicine, Pittsburgh (Price, Spotts, Panny, Griffo, Degutis, Cruz, Bell, Do-Nguyen, Wallace, Howland); Baylor College School of Medicine and Michael E. DeBakey VA Medical Center, Houston (Mathew).
Michael E. DeBakey VA Medical Center · US

Funding

University of Pittsburgh Clinical and Translational Science InstituteUL1TR001857 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2016 to 2025
$129.3M
Testing a Synergistic, Neuroplasticity-Based Intervention for Depressive NeurocognitionR01MH113857 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PRICE, REBECCA · 2017 to 2021
$2.4M
NCATS NIH HHS UL1 TR001857NIMH NIH HHS R01 MH113857
6 · The paper itself

Abstract

objectiveIntravenous ketamine, which displays rapid antidepressant properties, is posited to reverse depression by rapidly enhancing neuroplasticity. The authors tested whether an automated, computer-based approach could efficiently leverage enhanced neuroplasticity to extend the durability of rapid clinical response.

methodsA total of 154 adults (ages 18-60) with treatment-resistant unipolar depression were randomized in a double-blind, parallel-arm design to receive an active/active treatment combination (ketamine plus active "automated self-association training" [ASAT]; N=53) or one of two control arms that lacked either the active drug component (saline plus active ASAT; N=51) or the active behavioral component (ketamine plus sham ASAT; N=50). One day after a single infusion of intravenous ketamine (0.5 mg/kg over 40 minutes) or inert placebo (saline), active ASAT-targeting self-worth through automated "evaluative conditioning" training delivered by computer-or sham ASAT (consisting of identical computer tasks that included no positive or self-referential stimuli) was given, delivered twice daily over 4 consecutive days (eight sessions, ≤20 minutes per session). The prespecified primary outcome measure throughout the main (30-day) study period was score on the Montgomery-Åsberg Depression Rating Scale (MADRS).

resultsKetamine rapidly and significantly reduced depression scores at 24 hours postinfusion (group-by-time interaction: standardized beta [β]=-1.30, 95% CI=-1.89, -0.70; t=-4.29, df=150). In intent-to-treat linear mixed models, depression scores in the ketamine+ASAT group remained significantly and stably low over the 30-day study period relative to those of the saline+ASAT group (β=-0.61, 95% CI=-0.95, -0.28; t=-3.62, df=148). By contrast, depression scores following ketamine+sham treatment followed a significant, increasing linear trajectory from 24 hours to 30 days, approaching the levels observed in the saline+ASAT group (group-by-time interaction relative to the saline+ASAT group: β=0.015, 95% CI=0.003, 0.03; t=2.35, df=568).

conclusionsAfter priming the brain with ketamine, training positive self-associations could provide an efficient, low-cost, portable, noninvasive, and highly dissemination-ready strategy for leveraging and extending ketamine's rapid antidepressant effects.

Indexed as

Depressive Disorder, Treatment-ResistantKetamineAdolescentAdultAntidepressive AgentsDouble-Blind MethodExcitatory Amino Acid AntagonistsHumansMiddle AgedTreatment OutcomeYoung AdultAntidepressive AgentsExcitatory Amino Acid AntagonistsKetamineCognition/Learning/MemoryComputersDepressive DisordersDigital TherapeuticsKetamine/EsketamineMajor Depressive Disorder

Identifiers

PMID36128684
PMCPMC9722511
OpenAlexW4296710292

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.